Daiichi Sankyo To Submit NDA For Inavir In Japan By Year End
This article was originally published in PharmAsia News
Executive Summary
Following positive Phase III results for anti-influenza treatment Inavir (laninamivir), Daiichi Sankyo is preparing to submit an NDA for Inavir.